GlassScriptPhysician profile
Franchesca T Sanchez
NPI 1073271136
$2,915.71
in general payments reported to CMS, 2019-2025
20 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $446 · 2024: $983 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,886 · Education: $29.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,886.45 |
| Education | $29.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,163.22 | 2023-2025 | Repatha, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $379.30 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $351.28 | 2023-2025 | Farxiga, Saphnelo |
| Xeris Pharmaceuticals, INC. | $220.60 | 2025 | Recorlev |
| Novo Nordisk INC | $204.28 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $123.66 | 2023 | Arexvy |
| Lundbeck LLC | $120.68 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $48.27 | 2025 | |
| Dexcom, INC. | $43.14 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $34.58 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.24 | 2023 | Jardiance |
| Abbvie INC. | $25.81 | 2025 | |
| Alnylam Pharmaceuticals INC. | $25.80 | 2024 | Onpattro |
| Lilly USA, LLC | $24.74 | 2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $23.49 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $23.34 | 2024 | Injectafer |
| Astellas Pharma US INC | $22.03 | 2023 | Veozah |
| Shield Therapeutics INC | $20.32 | 2025 | |
| Aurinia Pharma U.S., INC. | $19.56 | 2023 | Lupkynis |
| Pfizer INC. | $15.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franchesca Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.